Pemetrexed Market Size & Trends 2020- expected to reach US$ 2347.6 Mn With CAGR of 1.3% by 2026 | Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, – Medgadget

May 13th, 2022 Releases
Global Pemetrexed Market
Overview:
Pemetrexed is a chemotherapy drug often used to treat non-small cell lung cancer (NSCLC) and pleural mesothelioma. The U.S. Food and Drug Administration (USFDA) has approved pemetrexed to treat malignant pleural mesothelioma and advanced/metastatic NSCLC.


Pemetrexed can be used alone or in combination with certain drugs to treat various diseases;
Pemetrexed, in combination with cisplatin, can be used to treat patients with locally advanced or metastatic nonsquamous NSCLC.
It can be used as a single agent maintain and treat people with locally advanced or metastatic nonsquamous NSCLC, whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
It can be used as a single agent to treat people with recurrent metastatic nonsquamous NSCLC after prior chemotherapy.
Pemetrexed, in combination with cisplatin, can be used to treat people with malignant pleural mesothelioma (MPM) whose disease is unrespectable or who are otherwise not candidates for curative surgery.
To Get more information Request for Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/2458
Drivers:
Increasing adoption of pemetrexed and frequent approvals & launches of pemetrexed generics are expected to boost the growth of the global pemetrexed market during the forecast period. Eli Lilly and Company sells pemetrexed under brand name Alimta. Alimta is a patented drug and it is protected by vitamin regimen patent (2021), pediatric exclusivity (2022) in the U.S., and a vitamin regimen patent (2021) in major European countries, and patents covering use to treat cancer concomitantly with vitamins (2021) in the Japan. However, the patent for Alimta has expired in 2015 in Japan and European countries, and expired in 2017 in the United States.
Few market players have already gained regulatory approvals for pemetrexed generics and are planning to launch them in the coming future. Moreover, with the launch of affordable generic of pemetrexed, the adoption of pemetrexed is also expected to increase.
For instance, in July 2018, the German Federal Patent Court declared the German section of European patent EP 1 313 508 for Alimta, void. Moreover, in July 2018, Stadapharm GmbH, announced the launched of generic version of Alimta, named pemetrexed STADA, in Europe.
Furthermore, Eli Lilly and Company is currently engaged in research and development and is planning to expand the indication of Alimta. For instance, in June 2018, Eli Lilly and Company received FDA approval for ALIMTA to treat people with metastatic nonsquamous NSCLC (in combination with carboplatin), irrespective of PD-L1 expression status. This in turn is expected to aid in the growth of the global pemetrexed market.
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables& Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-pdf/2458
Regional Insights:
North America is expected to witness robust growth in the global pemetrexed market due to the increasing prevalence of NSCLC and its high treatment rate in the region, especially in the United States. For example, according to Eli Lilly and Company, in 2017, pemetrexed (Alimta) generated around 50% of its revenue from the U.S.
Furthermore, according to the American Cancer Society, in the U.S., lung cancer (both small cell and non-small cell) is the second most common cancer in both men and women, and around 13% of all new cancer cases are lung cancer. Moreover, according to the same source, in 2019, more than 228,150 new lung cancer cases would be diagnosed in this region, and survival rate for NSCLC in stage IA1 is about 92%, stage IB is about 68%, stage IIIA is about 36%, stage IIIC is about 13%, and stage IIIC is about 13%.
Competitive landscape:
Major players active in the global pemetrexed market are Eagle Pharmaceuticals, Inc., Stada Arzneimittel AG, and Eli Lilly and Company, among others.
Purchase This Premium Report With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/2458
Table of Contents
View Press Release: https://www.coherentmarketinsights.com/press-release/pemetrexed-market-to-surpass-us-23476-mn-threshold-by-2026-1262
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: [email protected]
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Sign up and submit a press release
Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.

Read More

source

Related posts

Leave a Reply

Your email address will not be published.